Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in
primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP
is dendritic cells transfected with mRNA of survivin, hTERT og autologous tumor stem cells
derived from tumorspheres.